Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Phase 2 Clinical Trial to Assess the Efficacy and Safety of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis Patients.

NCT02332473 is registered in ClinicalTrials.gov with Xiamen Amoytop Biotech Co., Ltd. as lead sponsor.

NCT NCT02332473
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02332473 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Phase 2 Clinical Trial to Assess the Efficacy and Safety of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis Patients.
Lead sponsor
Xiamen Amoytop Biotech Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2014
Completion date
August 31, 2016
Enrollment
110 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b